The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia

Leukemia

Volumn 26, Issue 7, 2012, Pages 1713-1717

  Whitman, S P ^a   Caligiuri, M A ^a   Maharry, K ^a,b   Radmacher, M D ^a,b   Kohlschmidt, J ^a   Becker, H ^a   Mrozek K ^a   Wu, Y Z ^a   Schwind, S ^a   Metzeler, K H ^a   Mendler, J H ^a   Wen, J ^a   Baer, M R ^c   Powell, B L ^d   Carter, T H ^e   Kolitz, J E ^f   Wetzler, M ^g   Carroll, A J ^h   Larson, R A ⁱ   Marcucci, G ^a   Bloomfield, C D ^a   more..

^a OHIO STATE UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d WAKE FOREST BAPTIST HEALTH   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^g ROSWELL PARK CANCER INSTITUTE   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁱ UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MIXED LINEAGE LEUKEMIA PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA; DISEASE FREE SURVIVAL; GENE DUPLICATION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; LETTER; MODIFIER GENE; NUCLEOTIDE SEQUENCE; PARTIAL TANDEM DUPLICATION; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TRISOMY;

ADULT; AGED; COHORT STUDIES; CYTOGENETIC ANALYSIS; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MICRORNAS; MIDDLE AGED; MYELOID-LYMPHOID LEUKEMIA PROTEIN; PROGNOSIS; SURVIVAL RATE; TANDEM REPEAT SEQUENCES; TRISOMY; TUMOR MARKERS, BIOLOGICAL;

EID: 84863775768     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.34     Document Type: Letter

References (15)

1. Mró zek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 2007; 109: 431-448.
2. Caligiuri MA, Strout MP, Lawrence D, Arthur DC, Baer MR, Yu F et al. Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res 1998; 58: 55-59.
3. Schnittger S, Kinkelin U, Schoch C, Heinecke A, Haase D, Haferlach T et al. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia 2000; 14: 796-804.
4. Döhner K, Tobis K, Ulrich R, Fröhling S, Benner A, Schlenk RF et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol 2002; 20: 3254-3261.
5. Whitman SP, Ruppert AS, Marcucci G, Mró zek K, Paschka P, Langer C et al. Longterm disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B Study. Blood 2007; 109: 5164-5167.
6. Schlenk RF, Döhner K, Kneba M, Götze K, Hartmann F, Del Valle F et al. Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Haematologica 2009; 94: 54-60.
7. Steudel C, Wermke M, Schaich M, Schäkel U, Illmer T, Ehninger G et al. Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia. Genes Chromosomes Cancer 2003; 37: 237-251.
8. Schnittger S, Dicker F, Kern W, Wendland N, Sundermann J, Alpermann T et al. RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. Blood 2011; 117: 2348-2357.
9. Whitman SP, Hackanson B, Liyanarachchi S, Liu S, Rush LJ, Maharry K et al. DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication. Blood 2008; 112: 2013-2016.
10. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.
11. Bullinger L, Döhner K, Bair E, Fröhling S, Schlenk RF, Tibshirani R et al. Use of geneexpression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004; 350: 1605-1616.
12. Popovic R, Riesbeck LE, Velu CS, Chaubey A, Zhang J, Achille NJ et al. Regulation of mir-196b by MLL and its overexpression by MLL fusions contributes to immortalization. Blood 2009; 113: 3314-3322.
13. Garća P, Frampton J. Hematopoietic lineage commitment: miRNAs add specificity to a widely expressed transcription factor. Dev Cell 2008; 14: 815-816.
14. Jin S, Zhao H, Yi Y, Nakata Y, Kalota A, Gewirtz AM. c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis. J Clin Invest 2010; 120: 593-606.
15. Guenther MG, Jenner RG, Chevalier B, Nakamura T, Croce CM, Canaani E et al. Global and Hox-specific roles for the MLL1 methyltransferase. Proc Natl Acad Sci USA 2005; 102: 8603-8608.